Dental anomalies in a child with craniometaphysial dysplasia

Pediatric Dentistry

Volumn 29, Issue 5, 2007, Pages 415-419

  Zhang, Hai ^a   Somerman, Martha J ^a   Berg, Joel ^a   Cunningham, Michael L ^a   Williams, Bryan ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Landstuhl Regional Medical Center   (United States)

Author keywords

Ankh gene; Craniometaphysial dysplasia; Enamel; Phosphate

Indexed keywords

ANKH PROTEIN, HUMAN; PHOSPHATE TRANSPORTER; PYROPHOSPHATE;

ARTICLE; CASE REPORT; CRANIOFACIAL MALFORMATION; DOMINANT GENE; GENETICS; HUMAN; INFANT; MALE; METABOLISM; MUTATION; TOOTH MALFORMATION;

CRANIOFACIAL ABNORMALITIES; DIPHOSPHATES; GENES, DOMINANT; HUMANS; INFANT; MALE; MUTATION; PHOSPHATE TRANSPORT PROTEINS; TOOTH ABNORMALITIES;

EID: 47149111634     PISSN: 01641263     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Nurnberg P, Thiele H, Chandler D, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphysial dysplasia. Nat Genet 2001;28:37-41.
2. Reichenberger E, Tiziani V, Watanabe S, et al. Autosomal dominant craniometaphysial dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet 2001;68:1321-6.
3. Richards A, Brain C, Dillon MJ, Bailey CM. Craniometaphysial and craniodiaphyseal dysplasia, head and neck manifestations, and management. J Laryngol Otol 1996;100:328-38.
4. Kim YH, Roh DH, Choi BY, Oh SH. Craniometaphysial dysplasia. Acta Otolaryngol 2005;125:797-800.
5. Mintz S, Velez I. Craniometaphysial dysplasia associated with obstructive sleep apnea syndrome. Dentomaxillofac Radiol 2004;33:262-6.
6. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calciñcation and arthritis. Science 2000;289:265-70.
7. Goding JW, Terkeltaub R, Maurice M, Deterre P, Sali A, Belli SI. Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: Structure and function of the PC- 1 family. Immunol Rev 1998;161:11-26.
8. Whyte MP, Landt M, Ryan LM, et al. Alkaline phosphatase: Placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy. J Clin Invest 1995;95:1440-5.
9. Hayashibara T, Komura T, Sobue S, Ooshima T. Tooth eruption in a patient with craniometaphysial dysplasia: Case report. J Oral Pathol Med 2000;29:460-2.
10. Mitsiadis TA, Rahiotis C. Parallels between tooth development and repair: Conserved molecular mechanisms following carious and dental injury. J Dent Res 2004;83:896-902.
11. Thesleff I. Genetic basis of tooth development and dental defects. Acta Odontol Scand 2000;58:191-4.
12. Jung HS, Hitoshi Y, Kim HJ. Study on tooth development: Past, present, and future. Microsc Res Tech 2003;60:480-2.
13. Thesleff I, Mikkola M. The role of growth factors in tooth development. Int Rev Cytol 2002;217:93-135.
14. Papagerakis P, MacDougall M, Berdal A. Differential epithelial and mesenchymal regulation of tooth-specific matrix proteins expression by 1.25-dihydroxyvitamin D3 in vivo. Connect Tissue Res 2002;43:372-5.
15. Zeichner-David M, Oishi K, Su Z, et al. Role of Hertwig's epithelial root sheath cells in tooth root development. Dev Dyn 2003;228:651-63.
16. Thesleff I, Vaahtokari A, Kettunen P, Aherg T. Epithelial-mesenchymal signaling during tooth development. Connect Tissue Res 1995;32:9-15.
17. Gurley KA, Chen H, Guenther C, et al. Mineral formation in joints caused by complete or joint-specific loss of ANK function. J Bone Miner Res 2006;21:1238-47.
18. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
19. Anderson HC, Harmey D, Camacho NP, et al. Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double -deficient mice. Am J Pathol 2005;166:1711-20.
20. Nociti FH Jr, Berry JE, Foster BL, et al. Cementum: A phosphate-sensitive tissue. J Dent Res 2002;81:817-21.
21. van den Bos T, Handoko G, Niehof A, et al. Cementum and dentin in hypophosphatasia. J Dent Res 2005;84:1021-5.
22. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006;38:1248-50.
23. Pereira CM, de Andrade CR, Vargas PA, Coletta RD, de Almeida OP, Lopes MA. Dental alterations associated with X-linked hypophosphatemic rickets. J Endod 2004;30:241-5.
24. Fleisch H. Diphosphonates: History and mechanisms of action. Metab Bone Dis Relat Res 1981;3:279-87.
25. Rodan GA. Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol 1998;38:375-88.
26. Terkeltaub R, Lotz M, Johnson K, et al. Parathyroid hormone-related proteins is abundant in osteoarthritic cartilage, and the parathyroid hormone-related protein 1-173 isoform is selectively induced by transforming growth factor beta in articular chondrocytes and suppresses generation of extracellular inorganic pyrophosphate. Arthritis Rheum 1998;41:2152-64.
27. Terkeltaub RA. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001;281:C1-11.
28. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyper-phosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004;23:421-32.
29. Miao D, Bai X, Panda DK, Karaplis AC, Goltzman D, McKee MD. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone 2004;34:638-47.
30. Prie D, Beck L, Urena P, Friedlander G. Recent findings in phosphate homeostasis. Curr Opin Nephrol Hypertens 2005;14:318-24.
31. Beertsen W, VandenBos T, Everts V. Root development in mice lacking functional tissue non-specific alkaline phosphatase gene: Inhibition of acellular cementum formation. J Dent Res 1999;78:1221-9.
32. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006;24:945-52.
33. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.
34. Woo SB, Hellstein JW, Kalmar JR. Narrative review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
35. Ahmad FU, Mahapatra AK, Mahajan H. Craniofacial surgery for craniometaphysial dysplasia. Neurol India 2006;54:97-9.
36. Day RA, Park TS, Ojemann JG, Kaufman BA. Foramen magnum decompression for cervicomedullary encroachment in craniometaphysial dysplasia: Case report. Neurosurgery 1997;41:960-4.
37. Puri P, Chan J. Craniometaphysial dysplasia: Ophthalmic features and management. J Pediatr Ophthalmol Strabismus 2003;40:228-31.
38. Sheppard WM, Shprintzen RJ, Tatum SA, Woods CI. Craniometaphysial dysplasia: A case report and review of medical and surgical management. Int J Pediatr Otorhinolaryngol 2003;67:687-93.